Top

Published in:

01-06-2017 | Review Article

Surgical management of medullary thyroid carcinoma

Authors: Agathoklis Konstantinidis, Michael Stang, Sanziana A. Roman, Julie Ann Sosa

Published in: Updates in Surgery | Issue 2/2017

Abstract

Medullary thyroid cancer (MTC) is a malignant tumor of the parafollicular C cells of the thyroid and comprises only 1–2% of all thyroid cancer cases. Unlike most differentiated thyroid cancer, MTC is associated with a mean survival of 8.6 years and accounts for a disproportionate 8.6% of thyroid cancer deaths. Surgery is the mainstay of treatment for loco-regional disease and the only current means of cure for MTC. The relatively low incidence of MTC has made the comprehensive study of this disease difficult and most research to date has been based largely on single institution, retrospective, and/or non-randomized studies. Despite various professional organizations such as the American Thyroid Association establishing guidelines for the diagnosis and treatment of patients with MTC, there is still significant variation in actual practice patterns with regard to the extent of surgery, as well as the management of persistent or recurrent disease. The purpose of this review is to discuss the latest updates in the surgical treatment of MTC, as well as the management of locally advanced, recurrent, and metastatic disease based on the most recent data and expert consensus guidelines.

Hazard JB, Crile G Jr (1959) Medullary [solid] carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 19:152–161CrossRefPubMed

Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610CrossRefPubMedPubMedCentral

Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9):2134–2142CrossRefPubMed

Veiga LH, Neta G, Aschebrook-Kilfoy B, Ron E, Devesa SS (2013) Thyroid cancer incidence patterns in Sao Paulo, Brazil, and the U.S. SEER program. Thyroid 23(6):748–757CrossRefPubMedPubMedCentral

Machens A, Schneyer U, Holzhausen HJ et al (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029–2034CrossRefPubMed

Scollo C, Baudin E, Travagli J et al (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol 88:2070–2075CrossRef

Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95:586–591CrossRefPubMed

Bumming P, Ahlman H, Nilsson B, Nilsson O, Wangberg B, Jansson S (2008) Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma? Langenbecks Arch Surg 393:699–703CrossRefPubMed

Pelizzo MR, Boschin IM, Bernante P et al (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33:493–497CrossRefPubMed

10.

Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak KDS (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775–783CrossRefPubMedPubMedCentral

11.

Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JWA (2012) European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 1:5–14CrossRefPubMedPubMedCentral

12.

Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR (2014) British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol 81(Suppl 1):1–122CrossRef

13.

Grande E, Santamaría Sandi J, Capdevila J, Navarro González E, Zafón Llopis C, Ramón Y, Cajal Asensio T, Gómez Sáez JM, Jiménez-Fonseca P, Riesco-Eizaguirre G, Galofré JC (2016) Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI). Clin Transl Oncol 18(8):769–775CrossRefPubMed

14.

NCCN Clinical Practice Guidelines in Oncology (2016) Medullary thyroid carcinoma. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf

15.

Panigrahi B, Roman SA, Sosa JA (2010) Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol 17:1490–1498CrossRefPubMed

16.

Leboulleux S, Baudin E, Travagli JP, Schlumberger M (2004) Medullary thyroid carcinoma. Clin Endocrinol Oxf 61(3):299–310CrossRefPubMed

17.

Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H et al (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6(1):70–74CrossRefPubMed

18.

Howe JR, Norton JA, Wells SJ (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114:1070–1077PubMed

19.

Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Mulligan LM et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 International RET mutation consortium analysis. JAMA 276(19):1575–1579CrossRefPubMed

20.

Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525CrossRefPubMed

21.

Machens A, Holzhausen HJ, Thanh PN, Dralle H (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134(3):425–431CrossRefPubMed

22.

Zhou L, Chen B, Zhao M, Zhang H, Liang B (2015) Sonographic features of medullary thyroid carcinoma according to tumor size: comparison with papillary thyroid carcinoma. J Ultrasound Med 34(6):1003–1009CrossRefPubMed

23.

Kim SH, Kim BS, Jung SL, Lee JW, Yang PS, Kang BJ, Lim HW, Kim JY, Whang IY, Kwon HS, Jung CK (2009) Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol 10:101–105CrossRefPubMedPubMedCentral

24.

Lee S, Shin JH, Han BK, Ko EY (2010) Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. Am J Roentgenol 194:1090–1094CrossRef

25.

Pusztaszeri MP, Bongiovanni M, Faquin WC (2014) Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol 21(1):26–35CrossRefPubMed

26.

Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M (2007) Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 17(7):635–638CrossRefPubMed

27.

Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163–168CrossRefPubMed

28.

Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B (1997) Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 82:1589–1593CrossRefPubMed

29.

Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S (2007) Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 92:450–455CrossRefPubMed

30.

Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA (2008) Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 93(6):2173–2180CrossRefPubMed

31.

Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E, Conte-Devolx B (1997) Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 82:338–341CrossRefPubMed

32.

Borchhardt KA, Horl WH, Sunder-Plassmann G (2005) Reversibility of ‘secondary hypercalcitoninemia’ after kidney transplantation. Am J Transplant 5:1757–1763CrossRefPubMed

33.

Schuetz M, Duan H, Wahl K, Pirich C, Antoni A, Kommata S, Kletter K, Dudczak R, Karanikas G, Willheim M (2006) T lymphocyte cytokine production patterns in Hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Res 26:4591–4596PubMed

34.

Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed

35.

Machens A, Ukkat J, Hauptmann S, Dralle H (2007) Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 142(3):289–293CrossRefPubMed

36.

Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880–887CrossRefPubMedPubMedCentral

37.

Greenblatt DY, Elson D, Mack E et al (2007) Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 30:108–112CrossRefPubMed

38.

Fialkowski E, DeBenedetti M, Moley J (2008) Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32:754–765CrossRefPubMed

39.

Kebebew E, Kikuchi S, Duh QY, Clark OH (2000) Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135:895–901CrossRefPubMed

40.

Machens A, Dralle H (2013) Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 257(4):751–757CrossRefPubMed

41.

Tufano RP, Bishop J, Wu G (2012) Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 122(7):1634–1640CrossRefPubMed

42.

Dackiw APB (2010) The surgical management of medullary thyroid cancer. Otolaryngol Clin N Am 43:365–374CrossRef

43.

Meijer JA, Bakker LE, Valk GD, de Herder WW, de Wilt JH, Netea-Maier RT, Schaper N, Fliers E, Lips P, Plukker JT, Links TP, Smit JA (2013) Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur J Endocrinol 168:779–786CrossRefPubMed

44.

Brierley JD, Tsang RW (2008) External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin N Am 37:497–509CrossRef

45.

Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD (2010) Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 102:175–178CrossRefPubMedPubMedCentral

46.

Fife KM, Bower M, Harmer CL (1996) Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 22:588–591CrossRefPubMed

47.

Terezakis SA, Lee NY (2010) The role of radiation therapy in the treatment of medullary thyroid cancer. J Natl Compr Cancer Netw 8:532–540 (quiz 541) CrossRef

48.

Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4):305–310CrossRefPubMed

49.

Zenaty D, Aigrain Y, Peuchmaur M et al (2009) Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A [codon 634] and 2B. Eur J Endocrinol 160:807–813CrossRefPubMed

50.

Kloos RT, Eng C, Evans DB et al (2009) Medullary Thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612CrossRefPubMed

51.

Romei C, Tacito A, Molinaro E, Agate L, Bottici Valeria et al (2015) Twenty years lesson learning: how does the RET gene screening test impact clinical management of medullary thyroid cancer. Clin Endocrinol (Oxford) 82(6):892–899CrossRef

52.

Baloch ZW, LiVolsi VA (2006) Microcarcinoma of the thyroid. Adv Anat Pathol 13:69–75CrossRefPubMed

53.

Ogilvie JB, Patel KN, Heller KS (2010) Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas. Surgery 148:1222–1226CrossRefPubMed

54.

Hamy A, Pessaux P, Mirallie E et al (2005) Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol 31:774–777CrossRefPubMed

55.

Pillarisetty V, Katz S, Ghossein R, Tuttle R, Shaha A (2009) Micromedullary thyroid cancer: how micro is truly micro? Ann Surg Oncol 16:2875–2881CrossRefPubMed

56.

Peix JL, Braun P, Saadat M, Berger N, El Khazen M, Mancini F (2000) Occult micro medullary thyroid carcinoma: therapeutic strategy and follow-up. World J Surg 24:1373–1376CrossRefPubMed

57.

Kazaure HS, Roman S, Sosa JA (2012) Medullary thyroid microcarcinoma. A population-level analysis of 310 patients. Cancer 118:620–627CrossRefPubMed

58.

Beressi N, Campos JM, Beressi JP et al (1998) Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of 80 cases. Thyroid 8:1039–1044CrossRefPubMed

59.

Ismailov SI, Piulatova NR (2004) Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11:357–363CrossRefPubMed

60.

Elisei R, Pinchera A (2012) Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol 8:466–475CrossRefPubMed

61.

Lindsey SC, Ganly I, Palmer F, Tuttle RM (2015) Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 25:242–249CrossRefPubMed

62.

Tuttle RM, Ganly I (2013) Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol 49(695–701):12

63.

Yang JH, Lindsey SC, Camacho CP, Valente FO, Germano-Neto F, Machado AL et al (2015) Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer. Clin Endocrinol [Oxf] 83:938–942CrossRef

64.

Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084CrossRefPubMed

65.

Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537–1542CrossRefPubMedPubMedCentral

66.

Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134–141CrossRefPubMed

67.

Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639–3646CrossRefPubMedPubMedCentral

68.

Deshpande HA, Sheth K, Sosa JA, Roman S (2012) Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer. Clin Med Insights Oncol 6:355–362PubMedPubMedCentral

69.

Schoffski P, Elisei R, Muller S et al (2012) An international, double-blind, randomized, placebo-controlled phase III trial [EXAM] of cabozantinib [XL-184] in medullary thyroid carcinoma [MTC] patients [pts] with documented RECIST progression at baseline. J Clin Oncol 30:5508

70.

Cabanillas ME, Hu MI, Jimenez C (2014) Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat-and with which drug-those are the questions. J Clin Endocrinol Metab 99:4390–4396CrossRefPubMedPubMedCentral

71.

Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C et al (2013) Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther 30:945–966CrossRefPubMedPubMedCentral

Title: Surgical management of medullary thyroid carcinoma
Authors: Agathoklis Konstantinidis
Michael Stang
Sanziana A. Roman
Julie Ann Sosa
Publication date: 01-06-2017
Publisher: Springer Milan
Published in: Updates in Surgery / Issue 2/2017
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-017-0443-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Surgical management of medullary thyroid carcinoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Video-assisted endocrine neck surgery: state of the art

Open adrenalectomy in the era of laparoscopic surgery: a review

Neuromonitoring in endoscopic and robotic thyroidectomy

Locally invasive thyroid cancer: options for a treatment

Approach to thyroid carcinoma in pregnancy

Updates in primary hyperparathyroidism